Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gottlieb to leave FDA

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb will return to the American Enterprise Institute following his resignation from the agency, effective Jan. 16. Gottlieb will join former FDA/CMS chief Mark McClellan, who joined an AEI/Brookings Institution collaborative center in November after departing CMS in October. Gottlieb is the second senior advisor to von Eschenbach to announce a departure for January: FDA Chief of Staff Patrick Ronan recently said he would resign his post effective Jan. 5...

You may also be interested in...



Stockwatch: Subdued Virtual J.P. Morgan Conference Prefaces Full-Year Earnings Season

Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.

Government Report Outlines Costs, Savings Of Major Regs

The HHS was responsible for the most major regulations over the last few years of any agency, an OMB report shows.

J.P. Morgan Extras: Pandemic Impact on Launch, Production, Development And More

Additional views from the virtual J.P. Morgan Healthcare Conference on ways the COVID-19 pandemic has affected business practices and lessons learned for the future.

Topics

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel